论文部分内容阅读
心肌梗死的预后由左室功能所决定。心梗后心肌发生坏死,病理性重构,都可使心肌功能受损,而发生心衰,导致心梗预后不佳,故临床上防止或减少心梗后的左室重构是一个很重要的战略目标。卡维地洛(Carvedilol)是一种血管扩张剂,是非选择性β和α受体阻滞剂,其静脉注射或口服在充血性心衰中的作用早已有人证实,最近本文作者通过研究发现应用卡维地洛可安全有效地减少心脏意外的发生,同时证实其能减少左室射血分数小于45％病人的左室体积及室壁的不正常运动,从而证明了卡维地洛在减少心梗后心衰病人发生左室重构中的重要作用。
The prognosis of myocardial infarction is determined by left ventricular function. Myocardial necrosis after myocardial infarction, pathological remodeling, myocardial function can be impaired, and the occurrence of heart failure, leading to poor prognosis of myocardial infarction, it is clinically prevent or reduce left ventricular remodeling after myocardial infarction is a very important Strategic goal. Carvedilol, a vasodilator, is a nonselective beta and alpha blocker whose role in IV or oral congestive heart failure has long been confirmed. The authors have recently found that use of Carvedilol safe and effective in reducing the incidence of cardiac accidents, while confirming its ability to reduce LV ejection fraction of less than 45% of patients with left ventricular volume and abnormal movement of the ventricular wall, proving carvedilol in reducing heart Post-infarction heart failure occurs in left ventricular remodeling an important role.